肿瘤细胞治疗研究
英文原题：The new era of prostate-specific membrane antigen-directed immunotherapies and beyond in advanced prostate cancer: a review.
The new era of prostate-specific membrane antigen-directed immunotherapies and beyond in advanced prostate cancer: a review.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
前列腺癌中免疫检查点抑制剂缺乏成功，可能是多因素导致的，这促使了其他多种新型免疫治疗技术的开发和研究，包括抗体药物偶联物、T 细胞重定向双特异性疗法、癌症疫苗和 CAR-T 细胞疗法。
由于免疫检查点抑制剂治疗前列腺癌未获成功（可能涉及多种因素），研究人员开发并研究了多种新型免疫治疗技术，包括抗体药物偶联物、T细胞重定向双特异性疗法、癌症疫苗和CAR-T 细胞疗法。前列腺特异性膜抗原（PSMA）是一种肿瘤相关抗原（TAA），在转移性前列腺癌中高表达，且已被验证是有效的放射性核素治疗靶点。尽管PSMA目前是这些新型免疫治疗技术的首选靶点，但它未必是免疫治疗的理想靶点，其他潜在可靶向TAA也值得进一步探索。本文综述多种PSMA靶向治疗，以及PSMA以外免疫治疗的其他潜在靶点。
The lack of success in prostate cancer from immune checkpoint inhibitors, which is likely multifactorial, has led to the development and investigation of a number of other novel immunotherapeutic techniques, including antibody-drug conjugates, T-cell redirected bispecific therapies, cancer vaccines and chimeric antigen receptor T-cell therapies. Prostate-specific membrane antigen (PSMA) is a tumour-associated antigen (TAA) that is highly expressed in metastatic prostate cancer and has been validated as an effective target for radionuclide treatment. But while PSMA has thus far been the 'front runner' target for these novel immunotherapeutic techniques, it may not be the ideal target for immunotherapy and there are other potential targetable TAAs that will require further exploration. This review will focus on these various PSMA-directed therapies, as well as other potential targets for immunotherapy beyond PSMA.
MEMBER ACCOUNT
登录成功会直接打开下一页。
